Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

6017 - First national External Quality Assessement for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France

Date

30 Sep 2019

Session

Poster Display session 3

Topics

Translational Research

Tumour Site

Ovarian Cancer;  Melanoma;  Thoracic Malignancies

Presenters

Etienne Rouleau

Citation

Annals of Oncology (2019) 30 (suppl_5): v25-v54. 10.1093/annonc/mdz239

Authors

E. Rouleau1, K. Leroy2, K. Dufraing3, A. Harlé4, L. Lacroix5, K. Vanwelden6, M.G. Denis7, A. Lamy8, E. Dequeker3

Author affiliations

  • 1 Tumor Genetics, Gustave Roussy - Cancer Campus, 94 - Villejuif/FR
  • 2 Service De Genetique Et Biologie Moleculaire, Hôpital Cochin, 75014 - Paris/FR
  • 3 Quality, University Hospitals Leuven - Campus Gasthuisberg, 3000 - Leuven/BE
  • 4 Service De Biopathologie, Institut de Cancérologie de Lorraine - Alexis Vautrin, 54519 - Vandoeuvre les Nancy/FR
  • 5 Ammica, Inserm Us23/cnrs Ums3655, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 6 Biomedical Quality Assurance Research Unit, KU Leuven, 3000 - Leuven/BE
  • 7 Biochemistry, Nantes University Hospital, 44093 - Nantes/FR
  • 8 Pathology, Hop. Charles Nicolle, 76000 - Rouen/FR

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 6017

Background

The interpretation of testing results in molecular pathology is an essential phase. It is difficult to assesss this in external quality assessment on real samples. Here we propose a national measure of the concordance in the variant interpretation between laboratories participating in the national French quality control program Gen&tiss.

Methods

Laboratories were asked to interpret 5 variants each for melanoma, lung and colorectal cancers and 10 for ovarian cancer. These variants in KRAS, NRAS, BRAF, PIK3CA, PTEN, AKT1, TP53, EGFR, RAC1, KIT, BRCA1 and BRCA2 were not classical hotspots of mutation and 15 of these were annotated in OncoKB. A maximum of 25 variants was assessed per laboratories. Nine possible interpretations were proposed: from neutral to oncogenic and from no therapeutic impact to targeted by a drug. For each variant, a consensus score was determined based on public database as OncoKb and validated by 4 molecular experts with literature review. Three scores were possible: right answer (2 points), acceptable answer without clinical impact (1 point), wrong answer with clinical impact (0 points).

Results

60 laboratories participated to the program for variant interpretation. The average scores on 10 were 5.9 for colorectal (N = 52), 7.0 for lung (N = 49), 6.0 for melanoma (N = 49) and 7.0 for ovarian cancer (N = 25). For BRCA genes in ovarian cancer, there was a pilot project in 2017, in which 5 identical variants were proposed to interpretation. 18 laboratories participated both in 2017 and 2018: 50% performed better, 28% performed worse, 17% had similar results.

Conclusions

As test results have will have a direct impact on patient management, ensuring a correct interpretation becomes more and more important. This EQA could help to validate the interpretation process used in the laboratories (SOP and databases) and could be extend to the individual expertise.The average score is acceptable, yet improvable and it really depends on the variants proposed. International consensus guidelines equivalent to the ACMG classification of constitutional variants would be helpful to improve reproducibility and inter-laboratory homogeneity.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Gen&tiss - GFCO and AFAQAP.

Funding

AstraZeneca.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.